Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mulmin F is an oral fixed-dose combination nutritional supplement developed and marketed by Juggat Pharma (a division of Jagdale Industries). It is formulated as a capsule containing dried ferrous sulphate (150 mg), zinc sulphate monohydrate (61.8 mg), and folic acid (1.5 mg). Mulmin F is approved and marketed for the treatment and prevention of iron deficiency anemia, particularly during pregnancy and lactation. In pregnant and postpartum women, it helps support healthy fetal development, prevents neural tube defects, and reduces the risk of postpartum depression and postpartum hemorrhage associated with anemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mulmin F.